Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 25,000 shares of the stock in a transaction on Friday, August 4th. The shares were sold at an average price of $116.00, for a total value of $2,900,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, July 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $114.68, for a total value of $607,804.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $117.15, for a total value of $656,040.00.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down 0.27% on Tuesday, reaching $116.16. The company’s stock had a trading volume of 976,924 shares. The company has a market capitalization of $24.53 billion, a price-to-earnings ratio of 35.23 and a beta of 0.63. The company’s 50-day moving average is $117.28 and its 200 day moving average is $104.65. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The business had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.76 earnings per share. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

WARNING: “Insider Selling: Edwards Lifesciences Corporation (EW) VP Sells 25,000 Shares of Stock” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/08/insider-selling-edwards-lifesciences-corporation-ew-vp-sells-25000-shares-of-stock.html.

A number of research firms recently commented on EW. Bank of America Corporation increased their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Canaccord Genuity reissued a “buy” rating and issued a $155.00 price target (up from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Jefferies Group LLC increased their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Stifel Nicolaus reissued a “buy” rating and issued a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and issued a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $121.13.

A number of hedge funds have recently modified their holdings of the company. Torch Wealth Management LLC bought a new stake in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $1,635,000. Fox Run Management L.L.C. bought a new stake in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $1,383,000. Atria Investments LLC bought a new stake in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $352,000. Honkamp Krueger Financial Services Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 45.0% in the first quarter. Honkamp Krueger Financial Services Inc. now owns 11,836 shares of the medical research company’s stock worth $1,113,000 after buying an additional 3,673 shares during the last quarter. Finally, Gradient Investments LLC bought a new stake in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $288,000. Institutional investors and hedge funds own 84.15% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.